Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shanzhi Gu

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
International Journal of Cancer|July 26, 2021
Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trialXinni Chen, Shukui Qin, Shanzhi Gu, et al.
American Journal of Translational Research|November 10, 2017
Image-guided dendritic cell-based vaccine immunotherapy in murine carcinoma modelsBin Wang, Chong Sun, Sijia Wang, et al.
International Journal of Biological Sciences|January 3, 2024
VEGFA/NRP-1/GAPVD1 axis promotes progression and cancer stemness of triple-negative breast cancer by enhancing tumor cell-macrophage crosstalkLu Wang, Lifen Zhang, Lin Zhao, et al.
Chinese Medical Journal|June 9, 2026
Anti-PD-1 monoclonal antibody suppresses hepatitis B virus in patients with hepatocellular carcinomaChuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
Cancer Science|March 26, 2018
Ribosome display and selection of single-chain variable fragments effectively inhibit growth and progression of microspheres in vitro and in vivoShangke Huang, Lu Feng, Gaili An, et al.
BMC Cancer|May 6, 2025
FLT3LG modulates the infiltration of immune cells and enhances the efficacy of anti-PD-1 therapy in lung adenocarcinomaFengyu Zhao, Han Bai, Yiwei Liu, et al.
Liver Cancer|August 20, 2021
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 StudyShukui Qin, Zhenggang Ren, Yin-Hsun Feng, et al.
NPJ Precision Oncology|September 12, 2024
First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumorsJian Zhang, Yiqun Du, Yanchun Meng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2023
A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular CarcinomaChunhui Zhou, Yan Li, Jiaping Li, et al.
Eclinicalmedicine|October 17, 2022
Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind studyGuoliang Shao, Yuxian Bai, Xianglin Yuan, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
International Journal of Cancer|July 26, 2021
Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trialXinni Chen, Shukui Qin, Shanzhi Gu, et al.
American Journal of Translational Research|November 10, 2017
Image-guided dendritic cell-based vaccine immunotherapy in murine carcinoma modelsBin Wang, Chong Sun, Sijia Wang, et al.
International Journal of Biological Sciences|January 3, 2024
VEGFA/NRP-1/GAPVD1 axis promotes progression and cancer stemness of triple-negative breast cancer by enhancing tumor cell-macrophage crosstalkLu Wang, Lifen Zhang, Lin Zhao, et al.
Chinese Medical Journal|June 9, 2026
Anti-PD-1 monoclonal antibody suppresses hepatitis B virus in patients with hepatocellular carcinomaChuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
Cancer Science|March 26, 2018
Ribosome display and selection of single-chain variable fragments effectively inhibit growth and progression of microspheres in vitro and in vivoShangke Huang, Lu Feng, Gaili An, et al.
BMC Cancer|May 6, 2025
FLT3LG modulates the infiltration of immune cells and enhances the efficacy of anti-PD-1 therapy in lung adenocarcinomaFengyu Zhao, Han Bai, Yiwei Liu, et al.
Liver Cancer|August 20, 2021
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 StudyShukui Qin, Zhenggang Ren, Yin-Hsun Feng, et al.
NPJ Precision Oncology|September 12, 2024
First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumorsJian Zhang, Yiqun Du, Yanchun Meng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2023
A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular CarcinomaChunhui Zhou, Yan Li, Jiaping Li, et al.
Eclinicalmedicine|October 17, 2022
Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind studyGuoliang Shao, Yuxian Bai, Xianglin Yuan, et al.
Pageof 8